SFI
RCUS icon

Susquehanna Fundamental Investments’s Arcus Biosciences RCUS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,180
Closed -$204K – 832
2023
Q1 		$204K Sell
11,180
-5,182
-32% -$99K ﹤0.01% 863
2022
Q4 		$338K Buy
+16,362
New +$450K 0.01% 965
2020
Q4 		– Sell
-40,500
Closed -$694K – 1586
2020
Q3 		$694K Buy
40,500
+25,500
+170% +$570K 0.02% 764
2020
Q2 		$371K Buy
+15,000
New +$405K 0.02% 690

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Susquehanna Fundamental Investments's RCUS Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 11,180 shares — an estimated $204K sold.

Susquehanna Fundamental Investments first reported a position in RCUS in Q2 2020 and held it in 4 quarters. The position peaked at $694K in Q3 2020. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

  • Susquehanna Fundamental Investments reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 11,180 Arcus Biosciences shares in Q2 2023, an estimated $204K.
  • Susquehanna Fundamental Investments first reported a position in Arcus Biosciences in Q2 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Arcus Biosciences position peaked at $694K in Q3 2020.
  • 181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.